Tags

Type your tag names separated by a space and hit enter

Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II.
Arch Intern Med. 2009 Jan 26; 169(2):115-21; discussion 121.AI

Abstract

BACKGROUND

The use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is widespread for treatment of common symptoms such as headaches, muscular pain, and inflammation. In addition, the chemopreventive use of NSAIDs is increasingly common for heart disease and colon cancer. Evidence of a protective association with breast cancer risk has been inconsistent, and few data exist for premenopausal women.

METHODS

We assessed the associations for use of aspirin, other NSAIDs, and acetaminophen with breast cancer risk among premenopausal women in the prospective Nurses' Health Study II. In total, 112,292 women, aged 25 to 42 years and free of cancer in 1989, were followed up until June 2003. Multivariate relative risks and 95% confidence intervals were calculated by Cox proportional hazards models, adjusting for age and other important breast cancer risk factors.

RESULTS

Overall, 1345 cases of invasive premenopausal breast cancer were documented. Regular use of aspirin (> or = 2 times per week) was not significantly associated with breast cancer risk (relative risk, 1.07; 95% confidence interval, 0.89-1.29). Regular use of either nonaspirin NSAIDs or acetaminophen also was not consistently associated with breast cancer risk. Results did not vary by frequency (days per week), dose (tablets per week), or duration of use. Furthermore, associations with each drug category did not vary substantially by estrogen and progesterone receptor status of the tumor.

CONCLUSION

These data suggest that the use of aspirin, other NSAIDs, and acetaminophen is not associated with a reduced risk of breast cancer among premenopausal women.

Authors+Show Affiliations

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA 02115, USA. heather.eliassen@channing.harvard.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

19171806

Citation

Eliassen, A Heather, et al. "Use of Aspirin, Other Nonsteroidal Anti-inflammatory Drugs, and Acetaminophen and Risk of Breast Cancer Among Premenopausal Women in the Nurses' Health Study II." Archives of Internal Medicine, vol. 169, no. 2, 2009, pp. 115-21; discussion 121.
Eliassen AH, Chen WY, Spiegelman D, et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med. 2009;169(2):115-21; discussion 121.
Eliassen, A. H., Chen, W. Y., Spiegelman, D., Willett, W. C., Hunter, D. J., & Hankinson, S. E. (2009). Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Archives of Internal Medicine, 169(2), 115-21; discussion 121. https://doi.org/10.1001/archinternmed.2008.537
Eliassen AH, et al. Use of Aspirin, Other Nonsteroidal Anti-inflammatory Drugs, and Acetaminophen and Risk of Breast Cancer Among Premenopausal Women in the Nurses' Health Study II. Arch Intern Med. 2009 Jan 26;169(2):115-21; discussion 121. PubMed PMID: 19171806.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. AU - Eliassen,A Heather, AU - Chen,Wendy Y, AU - Spiegelman,Donna, AU - Willett,Walter C, AU - Hunter,David J, AU - Hankinson,Susan E, PY - 2009/1/28/entrez PY - 2009/1/28/pubmed PY - 2009/2/27/medline SP - 115-21; discussion 121 JF - Archives of internal medicine JO - Arch Intern Med VL - 169 IS - 2 N2 - BACKGROUND: The use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is widespread for treatment of common symptoms such as headaches, muscular pain, and inflammation. In addition, the chemopreventive use of NSAIDs is increasingly common for heart disease and colon cancer. Evidence of a protective association with breast cancer risk has been inconsistent, and few data exist for premenopausal women. METHODS: We assessed the associations for use of aspirin, other NSAIDs, and acetaminophen with breast cancer risk among premenopausal women in the prospective Nurses' Health Study II. In total, 112,292 women, aged 25 to 42 years and free of cancer in 1989, were followed up until June 2003. Multivariate relative risks and 95% confidence intervals were calculated by Cox proportional hazards models, adjusting for age and other important breast cancer risk factors. RESULTS: Overall, 1345 cases of invasive premenopausal breast cancer were documented. Regular use of aspirin (> or = 2 times per week) was not significantly associated with breast cancer risk (relative risk, 1.07; 95% confidence interval, 0.89-1.29). Regular use of either nonaspirin NSAIDs or acetaminophen also was not consistently associated with breast cancer risk. Results did not vary by frequency (days per week), dose (tablets per week), or duration of use. Furthermore, associations with each drug category did not vary substantially by estrogen and progesterone receptor status of the tumor. CONCLUSION: These data suggest that the use of aspirin, other NSAIDs, and acetaminophen is not associated with a reduced risk of breast cancer among premenopausal women. SN - 1538-3679 UR - https://www.unboundmedicine.com/medline/citation/19171806/Use_of_aspirin_other_nonsteroidal_anti_inflammatory_drugs_and_acetaminophen_and_risk_of_breast_cancer_among_premenopausal_women_in_the_Nurses'_Health_Study_II_ L2 - https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/archinternmed.2008.537 DB - PRIME DP - Unbound Medicine ER -